Resistant strains of bacteria feared from repeated use of ophthalmic antibiotics

Article

According to data recently published, repeated use of ophthalmic antibiotics post intraocular injections will cause an increase in incidences of resistant strains of conjunctival flora.

According to data recently published in Archives of Ophthalmology, repeated use of ophthalmic antibiotics post intraocular injections will cause an increase in incidences of resistant strains of conjunctival flora.

The study performed by Drs Stephen Kim and Hassanain Toma (Vanderbilt Eye Institute, Department of Ophthalmology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA) examined 48 eyes of 24 patients who were being treated for choroidal neovascularization (CNV) with unilateral intraocular injection.

Conjunctival cultures were taken bilaterally from both eyes (treated and untreated) at baseline and after each injection. All patients were randomly assigned to one of four different antibiotics and used only that antibiotic after each injection. Antibiotic susceptibility of the bacterial isolates was measured for 16 various antibiotics and pulse-field gel electrophoresis was used to analyse the bacteria DNA.

It was found that significant increases in drug resistance occurred in treated eyes, which led the team to conclude that conjunctival flora that is repeatedly exposed to antibiotics will result in resistant strains.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.